Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Applied StemCell Closes $19 Million Series D for Gene Editing Pipeline

publication date: Jun 6, 2016
Applied StemCell, a Bay-area gene-editing company, raised $19 million in a Series D funding from China investors. The company said it would use the funds to develop its pipeline of therapeutics for monogenic blood disorders and advance its CRISPR and Cas9 gene editing platform. Applied StemCell provides genetically modified human cell lines and transgenic animal models to researchers and also uses its gene editing technology to develop gene/stem cell-based gene therapies. The funding was led by HerMed Capital, a healthcare PE fund formed by Fosun Pharma and the SK Group, a Korean conglomerate. Additional investors included Ping An Ventures, Vi-Ventures and BioSciKin. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here